As of 2025-11-17, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -26.47. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 14,735.97 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -556.74 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 15.6x | 14.1x |
| Forward P/E multiples | 14.0x - 15.6x | 14.8x |
| Fair Price | (51.41) - (56.12) | (52.78) |
| Upside | -177.4% - -184.5% | -179.5% |
| Date | EV/EBITDA |
| 2025-11-14 | -26.47 |
| 2025-11-13 | -26.01 |
| 2025-11-12 | -26.41 |
| 2025-11-11 | -26.53 |
| 2025-11-10 | -25.24 |
| 2025-11-07 | -24.89 |
| 2025-11-06 | -25.21 |
| 2025-11-05 | -25.19 |
| 2025-11-04 | -24.74 |
| 2025-11-03 | -24.95 |
| 2025-10-31 | -25.18 |
| 2025-10-30 | -25.43 |
| 2025-10-29 | -26.55 |
| 2025-10-28 | -25.82 |
| 2025-10-27 | -25.50 |
| 2025-10-24 | -22.30 |
| 2025-10-23 | -22.15 |
| 2025-10-22 | -21.95 |
| 2025-10-21 | -22.34 |
| 2025-10-20 | -22.99 |
| 2025-10-17 | -22.53 |
| 2025-10-16 | -22.57 |
| 2025-10-15 | -23.12 |
| 2025-10-14 | -23.07 |
| 2025-10-13 | -22.89 |
| 2025-10-10 | -22.73 |
| 2025-10-09 | -22.49 |
| 2025-10-08 | -22.66 |
| 2025-10-07 | -22.29 |
| 2025-10-06 | -22.42 |
| 2025-10-03 | -21.82 |
| 2025-10-02 | -21.97 |
| 2025-10-01 | -22.04 |
| 2025-09-30 | -21.51 |
| 2025-09-29 | -21.51 |
| 2025-09-26 | -20.86 |
| 2025-09-25 | -20.50 |
| 2025-09-24 | -21.06 |
| 2025-09-23 | -21.36 |
| 2025-09-22 | -21.37 |
| 2025-09-19 | -21.65 |
| 2025-09-18 | -21.98 |
| 2025-09-17 | -21.25 |
| 2025-09-16 | -21.35 |
| 2025-09-15 | -21.35 |
| 2025-09-12 | -21.26 |
| 2025-09-11 | -21.73 |
| 2025-09-10 | -21.86 |
| 2025-09-09 | -22.04 |
| 2025-09-08 | -22.31 |